We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Trenev Trio®/Healthy Trinity® for Recurrent Gastrointestinal Symptoms

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01444859
Recruitment Status : Unknown
Verified December 2011 by Sprim Advanced Life Sciences.
Recruitment status was:  Active, not recruiting
First Posted : October 3, 2011
Last Update Posted : October 24, 2012
Information provided by (Responsible Party):

Study Description
Brief Summary:
Clinical trial to compare safety and effectiveness of 10-week supplementation with Trenev Trio®/Healthy Trinity® vs. placebo in otherwise healthy subjects with recurrent gastrointestinal symptoms.

Condition or disease Intervention/treatment Phase
Recurrent Gastrointestinal Symptoms Dietary Supplement: Trenev Trio®/Healthy Trinity® Dietary Supplement: Placebo Phase 2 Phase 3

Detailed Description:
This study is a double-blind, randomized, placebo-controlled, parallel group trial comparing the safety and effectiveness of supplementation with Trenev Trio®/Healthy Trinity® vs. placebo in otherwise healthy subjects with recurrent gastrointestinal symptoms. Subjects will be recruited and, following successful completion of a 2-week run-in period, will be randomized to Trenev Trio®/Healthy Trinity® or placebo and will consume their assigned study product daily for 10 weeks. The study endpoints of this trial include relief of overall gastrointestinal symptoms, acid indigestion, abdominal cramping, constipation, diarrhea, gas, and bloating as well as product safety over the 10-week supplementation period.

Study Design

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 120 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Effect of Trenev Trio®/Healthy Trinity® in Otherwise Healthy Adults With Recurrent Gastrointestinal Symptoms: a Double-blind, Randomized, Placebo-controlled, Parallel Group Study
Study Start Date : February 2012
Primary Completion Date : August 2012
Estimated Study Completion Date : November 2012
Arms and Interventions

Arm Intervention/treatment
Placebo Comparator: Placebo capsule
40 subjects allocated to daily placebo capsule for 10 weeks
Dietary Supplement: Placebo
Daily placebo for 10 weeks
Other Names:
  • Inactive
  • Control
Experimental: Trenev Trio®/Healthy Trinity®
80 subjects allocated to Trenev Trio®/Healthy Trinity® for 10 weeks
Dietary Supplement: Trenev Trio®/Healthy Trinity®
Trenev Trio®/Healthy Trinity® (1 capsule, 2x/day for 10 weeks), which offers a daily dose of: a) Lactobacillus acidophilus NAS strain (10 billion CFU), b) Bifidobacterium bifidum Malyoth strain (40 billion CFU), and c) Lactobacillus delbrueckii subspecies bulgaricus LB-51 strain (10 billion CFU)
Other Names:
  • Probiotic
  • Active

Outcome Measures

Primary Outcome Measures :
  1. Mean total Gastrointestinal Symptom Rating Scale (GSRS) score [ Time Frame: 10 weeks ]
  2. Gastrointestinal Quality of Life Index (GIQLI) total score [ Time Frame: 10 weeks ]

Secondary Outcome Measures :
  1. Gastrointestinal Symptom Rating Scale subscores [ Time Frame: 10 weeks ]
  2. Gas severity [ Time Frame: 10 weeks ]
  3. Bloating severity [ Time Frame: 10 weeks ]
  4. Acid indigestion severity [ Time Frame: 10 weeks ]
  5. Abdominal cramping severity [ Time Frame: 10 weeks ]
  6. Stool consistency (measured with Bristol Stool Form Scale) [ Time Frame: 10 weeks ]
  7. Stool frequency [ Time Frame: 10 weeks ]
  8. Concomitant medication use [ Time Frame: 10 weeks ]
  9. Adverse event frequency [ Time Frame: 10 weeks ]
  10. Adverse event severity [ Time Frame: 10 weeks ]

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  1. Age ≥18 years
  2. Body mass index between 18.5 through 39.9 kg/m2
  3. At least three symptoms rated between 4 to 6 in severity (moderate to severe discomfort) on a 1 to 7 scale, one of which must be acid indigestion as determined by the "Reflux Syndrome" score
  4. Self-reported "acid indigestion" symptoms (including pain/discomfort beneath the breastbone, bitter fluid in the mouth, or bloating/nausea after eating) at least 3 times per week over the previous 4 weeks
  5. Agree to use contraception throughout study period, unless postmenopausal or surgically sterile (females only)
  6. Able to understand and voluntarily consent to the study and understand it's nature and purpose including potential risks, and side effects

Exclusion Criteria:

  1. Any GSRS symptom rated a 7 in severity (very severe discomfort) on a 1 to 7 scale
  2. Diagnosed gastrointestinal disease/complication or functional bowel disorder (e.g. IBS, functional constipation, IBD, ulcer, etc.) based on physical examination or documented medical history that, in the investigator's opinion, may affect subject safety or confound the evaluation of the study endpoints
  3. Any non-gastrointestinal disease/complication that, in the investigator's opinion, may affect subject safety or confound the evaluation of the study endpoints
  4. Regular (>3 days per week) prescription medication use for any gastrointestinal disease/condition
  5. Recent (<6 months) abdominal surgery for any reason
  6. Immunodeficiency
  7. Recent change in anti-psychotic medication within the previous 3 months
  8. Systemic steroid use within the prior month, excluding regular use of asthma medication
  9. Pregnant female or breastfeeding
  10. Eating disorder
  11. Recent (within 2 weeks) antibiotic administration
  12. History of alcohol, drug, or medication abuse
  13. Daily consumption of probiotics, fermented milk, and/or yogurt
  14. Known allergies to any substance in the study product
  15. Participation in another study with any investigational product within 30 days of screening
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01444859

United States, California
Axis Clinical Trials
Los Angeles, California, United States, 90036
Sprim ALS
San Francisco, California, United States, 94109
United States, Pennsylvania
Research Across America
West Lawn, Pennsylvania, United States, 19609
United States, Texas
Research Across America
Carrollton, Texas, United States, 75010
United States, Virginia
Clinical Research Associates of Tidewater
Norfolk, Virginia, United States, 23507
Sponsors and Collaborators
Sprim Advanced Life Sciences
The National Institute of Probiotics
Principal Investigator: Duane Wombolt, MD Clinical Research Associates of Tidewater
Principal Investigator: Jeffrey Stewart, MD Research Across America
Principal Investigator: Michael Sinitsa, MD Research Across America
Principal Investigator: Helen Stacey, MD Diablo Clinical Research
Principal Investigator: Lydie Hazan, MD Axis Clinical Trials
Principal Investigator: JoAnn Hattner, MPH, RD Sprim ALS
More Information

Responsible Party: Sprim Advanced Life Sciences
ClinicalTrials.gov Identifier: NCT01444859     History of Changes
Other Study ID Numbers: 110725-SUS-NIP-GIS-RA
First Posted: October 3, 2011    Key Record Dates
Last Update Posted: October 24, 2012
Last Verified: December 2011

Additional relevant MeSH terms:
Gastrointestinal Diseases
Signs and Symptoms, Digestive
Digestive System Diseases
Signs and Symptoms